IP Library › Granted Patent US 12,427,141
Granted Patent B2
US 12,427,141 · App. 17/721,067 · Granted Sep 30, 2025

BYL719 (alpelisib) for use in the treatment of PIK3CA-related overgrowth spectrum (PROS-CLOVES syndrome)

Inventor: Guillaume Canaud (Paris, FR)
Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITÉ PARIS CITÉ; ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP)
A61K31/4439A61P43/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,427,141
App. No.
17/721,067
Granted
Sep 30, 2025
Kind
B2
Abstract

The present invention relates to a method of treating PIK3CA-Related Overgrowth Spectrum (PROS) more particularly, Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevi and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) syndrome. To date, there are no specific treatments for patients and no animal models of PROS to better understand the physiopathology of the disorder. Inventors developed a genetic mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719. Based on these results they treated two patients, one adult and one child, with severe CLOVES syndrome using BYL719. The drug had a robust efficiency on disease in the two patients inducing quick recovery of all affected organs. Thus, the invention relates to a method of treating PROS in a subject in need thereof comprising the step of administrating the subject with a therapeutically effective amount of BYL719.

Claims (30)

1. A method of treating a patient who is an adult having a PIK3CA-related overgrowth spectrum (PROS) disorder, comprising the steps of

identifying the subject as suffering from the PROS disorder having an overgrowth of multiple organs or tissues caused by a somatic mosaic mutation, wherein the PROS disorder is not an isolated venous malformation;

administering orally to the subject a therapeutically effective amount of BYL719, wherein the therapeutically effective amount of BYL719 is a starting dose of 250 mg daily; and

reversing the overgrowth of multiple organs or tissues.

2. The method of claim 1 , wherein the somatic mosaic mutation is a mutation in the PIK3CA gene selected from the group consisting of H1047R, E542K and E545K.

3. The method of claim 1 , wherein the PROS disorder is not responsive to treatment with rapamycin.

4. The method of claim 1 , wherein the PROS disorder is selected from the group consisting of

fibroadipose overgrowth;

megalencephaly-capillary malformation syndrome;

congenital lipomatous overgrowth, vascular malformations, epidermal nevi, skeletal and spinal anomalies and/or scoliosis (CLOVES) syndrome;

hemihyperplasia multiple lipomatosis; and

Klippel-Trenaunay syndrome.

5. The method of claim 4 , wherein the PROS disorder is congenital lipomatous overgrowth, vascular malformations, epidermal nevi, skeletal and spinal anomalies, and/or scoliosis (CLOVES) syndrome.

6. The method of claim 4 , wherein the PROS disorder is Klippel-Trenaunay syndrome.

7. The method of claim 1 , wherein the method treats a symptom selected from the group consisting of edema, venous dilation, vascular tumors, elevated brain natriuretic peptide blood level, proteinuria, kidney dysfunction, overgrown tissue, dysregulated adipose tissue, scoliosis, enlarged bony structures without progressive bony overgrowth, benign tumors, megalencephaly-capillary malformation, lipomatous asymmetric overgrowth of the trunk, epidermal nevi, lymphatic malformation, muscle hypertrophy, liver steatosis, and spleen disorganization.

8. A method of treating a patient who is a child having a PIK3CA-related overgrowth spectrum (PROS) disorder, comprising the steps of

identifying the subject as suffering from the PROS disorder having an overgrowth of multiple organs or tissues caused by a somatic mosaic mutation, wherein the PROS disorder is not an isolated venous malformation;

administering orally to the subject a therapeutically effective amount of BYL719, wherein the therapeutically effective amount of BYL719 is a starting dose of 50 mg daily; and

reversing the overgrowth of multiple organs or tissues.

9. The method of claim 8 , wherein the somatic mosaic mutation is a mutation in the PIK3CA gene selected from the group consisting of H1047R, E542K and E545K.

10. The method of claim 8 , wherein the PROS disorder is not responsive to treatment with rapamycin.

11. The method of claim 8 , wherein the PROS disorder is selected from the group consisting of

fibroadipose overgrowth;

megalencephaly-capillary malformation syndrome;

congenital lipomatous overgrowth, vascular malformations, epidermal nevi, skeletal and spinal anomalies and/or scoliosis (CLOVES) syndrome;

hemihyperplasia multiple lipomatosis; and

Klippel-Trenaunay syndrome.

12. The method of claim 11 , wherein the PROS disorder is congenital lipomatous overgrowth, vascular malformations, epidermal nevi, skeletal and spinal anomalies, and/or scoliosis (CLOVES) syndrome.

13. The method of claim 11 , wherein the PROS disorder is Klippel-Trenaunay syndrome.

14. The method of claim 8 , wherein the method treats a symptom selected from the group consisting of edema, venous dilation, vascular tumors, elevated brain natriuretic peptide blood level, proteinuria, kidney dysfunction, overgrown tissue, dysregulated adipose tissue, scoliosis, enlarged bony structures without progressive bony overgrowth, benign tumors, megalencephaly-capillary malformation, lipomatous asymmetric overgrowth of the trunk, epidermal nevi, lymphatic malformation, muscle hypertrophy, liver steatosis, and spleen disorganization.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2025
From: CANAUD, GUILLAUME
To: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITÉ PARIS DESCARTES; ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
Reel/Frame 071067/0733 →
MERGER Recorded May 8, 2025
From: UNIVERSITÉ DE PARIS DESCARTES
To: UNIVERSITÉ DE PARIS
Reel/Frame 071067/0788 →
CHANGE OF NAME Recorded Aug 25, 2023
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 064727/0194 →
Priority Claims (1)
EP 16305193 · Feb 19, 2016 · regional
Continuity (2)
Continuation 15998950
Related Publication 20220323428A1 · Oct 13, 2022
References Cited (36)
US 11433059B2 · Canaud · 2022 [cited by applicant]
WO WO2016187157A1 · 2016 [cited by applicant]
Uller et al (Seminars in Pediatric Surgery, 2014; 23(4):208-215) (Year: 2014). [cited by examiner]
Luks et al (J Pediatr 2015; 166(4):1048-54, see p. 1050, left, last paragraph) (Year: 2015). [cited by examiner]
Limaye et al., “Somatic Activating PIK3CA Mutations Cause Venous Malformation”, [cited by applicant]
Kurek et al., “Somatic Mosaic Activating Mutations in PIK3CA Cause CLOVES Syndrome”, [cited by applicant]
Vahidnezhad et al., “Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS)”, [cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/EP2017/053587, dated Aug. 24, 2017, 5 pages. [cited by applicant]
Mirzaa et al., “PIK3CA-Related Overgrowth Spectrum”, GeneReviews, pp. 1-30 (Aug. 2013), https://www.ncbi.nlm..nih.gov/books/NBK153722/pdf/Bookshelf NBK153722.pdf. [cited by applicant]
Crunkhorn, “PI3K inhibitor reverses overgrowth syndrome”, Nature Reviews Drug Discovery 17(8):545, doi:10.1038/nrd.2018.120 (2018). [cited by applicant]
Delestre et al., “Alpelisib administration reduced lymphatic malformations in a mouse model and in patients”, [cited by applicant]
Delestre et al., “Supplementary Materials for Alpelisib administration reduced lymphatic malformations in a mouse model and in patients”, [cited by applicant]
Ladraa et al., “PIK3CA gain-of-function mutation in adipose tissue induces metabolic reprogramming with Warburg-like effect and severe endocrine disruption”, [cited by applicant]
Morin et al., “Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib”, [cited by applicant]
Semple et al., “Cancer drug tackles overgrowth syndrome”, [cited by applicant]
Venot et al., “Targeted therapy in patients with PIK3CA-related overgrowth syndrome”, [cited by applicant]
FDA Accelerated Approval; https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accedlrated-approval. [cited by applicant]
“FDA approves alpelisib for PIK3CA-related overgrowth spectrum”, United States Food and Drug Administration (FDA) (2022). [cited by applicant]
“FDA Approves Novartis Vijoice® for Select Patients with PIK3CA-Related Overgrowth Spectrum”, American Pharmaceutical Review Press Release, Apr. 6, 2022, https://www.americanpharmaceuticalreview.com/1315-News/584880-FDA… [cited by applicant]
Novartis Annual Report 2023. [cited by applicant]
Adams et al., “Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies”, [cited by applicant]
Alomari, “Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome”, [cited by applicant]
Canaud et al., “A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations”, [cited by applicant]
Di Blasio et al., “PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations”, [cited by applicant]
Dompmartin et al., “Venous Malformation: update on etiopathogenesis, diagnosis & management”, [cited by applicant]
Forde et al., “Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome”, [cited by applicant]
Friedberg, “Gigantic Growth of the Right Leg”, Archives for Pathological Anatomy and Physiology vol. XL, Hn. 3u. 4 (1867). [cited by applicant]
Keppler-Noureuil et al., “PIK3CA-Related Overgrowth Spectrum (PROS): Diagnostic and Testing Eligibility Criteria, Differential Diagnosis, and Evaluation”, [cited by applicant]
Lopez Gutierrez et al., “Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (… [cited by applicant]
Luu et al., “Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study”, [cited by applicant]
Pagliazzi et al., “PIK3CA-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With Alpelisib”, [cited by applicant]
Parker et al., “Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum”, [cited by applicant]
Reis III et al., “Pulmonary thromboembolic events in patients with congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and spina;/skeletal abnormalities and Klippel-Trenaunay syndrome”, [cited by applicant]
Sapp et al., “Newly delineated syndrome of congenital/lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE) syndrome) in seven patients”, [cited by applicant]
Seront et al., “Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations”, [cited by applicant]
Zerbib et al., “Targeted therapy for capillary-venous malformations”, [cited by applicant]